Mantle cell lymphoma: therapeutic options in transplant-ineligible patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mantle cell lymphoma: therapeutic options in transplant-ineligible patients

Published:2019-04-25 Issue:11 Volume:60 Page:2622-2634
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Robak Tadeusz¹,Smolewski Piotr²,Robak Pawel²,Dreyling Martin³

Affiliation:

1. Department of Hematology, Medical University of Lodz, Lodz, Poland;

2. Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland;

3. Department of Medicine III, University Hospital Ludwig Maximilians University, Munich, Germany

Funder

Uniwersytet Medyczny w Lodzi

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1605511

Reference94 articles.

1. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

2. Mantle Cell Lymphoma

3. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

4. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

5. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STAT5B Suppresses Ferroptosis by Promoting DCAF13 Transcription to Regulate p53/xCT Pathway to Promote Mantle Cell Lymphoma Progression;Biologics: Targets and Therapy;2024-07

2. SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

3. Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis;Cancer Medicine;2023-05-06

4. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle‐cell lymphoma ineligible for intensive therapy: A network meta‐analysis;European Journal of Haematology;2023-03-23

5. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma;New England Journal of Medicine;2022-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3